INDIGO Trial: IDH Inhibitor Improves Progression-Free Survival in Grade 2 IDH1/2-Mutated Gliomas
There has been a lot of noise about the INDIGO trial – it is one of the only trials that has met its primary endpoints before the end of the trial, so the trial has been unblinded and those [...]